1. Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Epidemiology of SCCHN

5. Tumor-Infiltrating Lymphocytes Are Present in Some HNCs

6. Tumor Immunity Cycle Goal: Activated T Cells Kill Tumor Cells

7. Modulation of the Immune System Through Checkpoint Inhibitor Pathways

8. Challenges in SCCHN Treatment

9. Case Study 1: 65-Year-Old With Stage IVB, HPV-Positive, Oropharynx Cancer

10. Nivolumab: CheckMate 141 Efficacy Data

11. Nivolumab: Data Related to Prior Treatments

12. Nivolumab: CheckMate 141 Biomarker Data

13. Pembrolizumab: Trials in R/M SCCHN

14. Durvalumab: Study 1108

15. Case Study 2: 69-Year-Old Patient With Stage IVB, HPV-Negative Larynx Cancer

16. Pseudoprogression

17. Ongoing Studies

18. Pembrolizumab Plus Epacadostat: Preliminary Data

19. Immune-Related AEs

20. Hypothyroidism

21. Pneumonitis

22. Take Home Messages

23. Abbreviations

24. Abbreviations (cont)